Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Islet cell transplantation.

Federico Bertuzzi1, Simona Marzorati, Antonio Secchi

  • 1Unit of Cell Therapy for Type 1 Diabetes, San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, Italy. bertuzzi.federico@hsr.it

Current Molecular Medicine
|August 12, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Maturity onset diabetes of the young in pregnancy: management, treatment and neonatal outcomes-a systematic review.

Acta diabetologica·2026
Same author

The effect of forced infusion in phacoemulsification training: a comparative study.

International ophthalmology·2026
Same author

Sex Differences in Continuous Glucose Monitoring Metrics and Glucose Variability in Subjects with Type 1 Diabetes Treated with Advanced Hybrid Closed Loop Therapy: An Observational, Retrospective, One-Year Follow-Up Study.

Journal of clinical medicine·2025
Same author

LRRK2 kinase modulates glucose-stimulated insulin secretion via RAB8 phosphorylation and ciliogenesis.

Cellular and molecular life sciences : CMLS·2025
Same author

Real-World Effectiveness of Different Nutraceutical Formulations on Pain Intensity of Subjects with Diabetic Peripheral Neuropathy: An Observational, Retrospective, Case-Control Study.

Biomedicines·2025
Same author

Enhancing Type 2 Diabetes Care With CGM Integration: Insights From an Italian Expert Group.

Diabetes/metabolism research and reviews·2025

Islet cell transplantation offers a promising alternative for type 1 diabetes, restoring insulin independence and metabolic function in over 80% of patients. This somatic cell therapy improves glycemic control and reduces complications, with ongoing research into reducing immunosuppression.

Area of Science:

  • Endocrinology
  • Cell Therapy
  • Transplantation Immunology

Background:

  • Type 1 diabetes management often relies on insulin therapy or whole pancreas transplantation.
  • Islet cell transplantation presents a less invasive alternative for selected patients.
  • Islet isolation from the pancreas is a complex but established procedure.

Purpose of the Study:

  • To evaluate the efficacy and safety of islet cell transplantation in type 1 diabetic patients.
  • To assess the potential for restoring endogenous insulin secretion and metabolic control.
  • To review the benefits and ongoing advancements in islet cell transplantation protocols.

Main Methods:

  • Islet isolation involves collagenase digestion of pancreatic tissue followed by density gradient centrifugation.

Related Experiment Videos

  • Transplantation is performed via percutaneous trans-hepatic injection into the portal vein under local anesthesia.
  • Patient selection focuses on individuals with long-term type 1 diabetes and specific clinical criteria.

    • Main Results:

    • Islet transplantation successfully restores pancreatic endocrine function in over 80% of recipients, achieving insulin independence.
    • Patients experience improved glucose, protein, and lipid metabolism.
    • Significant benefits include better glycemic control (HbA1c), reduced hypoglycemia, and fewer long-term diabetic complications.

    Conclusions:

    • Islet cell transplantation is a safe and effective therapy for type 1 diabetes, offering significant metabolic benefits.
    • The procedure can restore endogenous insulin production and improve quality of life.
    • Current research focuses on optimizing immunosuppression protocols to enhance graft longevity and patient outcomes.